NIDDK encourages technology research in diabetes.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) actively supports technology-related research directed at development of new therapies for prevention and treatment of diabetes and its complications. Identification of the genetic and environmental contributors to diabetes and the molecular mechanisms through which they act will yield new targets for therapeutic development. Major efforts are also directed at development of beta-cell replacement therapy; improved methods for sensing glucose and delivering insulin; imaging technologies and other surrogate markers to detect disease progression; improved animal models for study of diabetes and its complications; and clinical trials to evaluate the safety and efficacy of new therapies. Application of genomic, proteomic and other new technologies to diabetes research, collaborations between diabetes researchers and researchers with technologies relevant to diabetes, and bench to bedside translational research are particularly encouraged. A variety of funding mechanisms are available to prospective researchers.
Fradkin
Judith
J
Division of Diabetes, Endocrinology, and Metabolic Diseases, NIDDK, NIH, Bethesda, Maryland 20892, USA. JF58S@nih.gov
D003920:Diabetes Mellitus / Q000517:prevention & control; D006801:Humans; D013677:Medical Laboratory Science; D009316:National Institutes of Health (U.S.); D012106:Research; D014481:United States